Title page

Effects of Phenobarbital on Expression of UDP-glucuronosyltransferase 1a6 and 1a7 in Rat Brain

Yukiko Sakakibara, Miki Katoh, Yuya Kondo, and Masayuki Nadai

Pharmaceutics, Faculty of Pharmacy, Meijo University; 150 Yagotoyama, Tenpaku-ku, Nagoya 468–8503, Japan
DMD#67436

Running title page

a) Running title: Phenobarbital alters brain UGT in rats

b) Correspondence author: Miki Katoh, PhD, Pharmaceutics, Faculty of Pharmacy, Meijo University; 150 Yagotoyama, Tenpaku-ku, Nagoya 468–8503, Japan. E-mail: mkatoh@meijo-u.ac.jp, Tel: +81-52-832-1151, Fax: +81-52-834-8090

c) Number of text pages: 28
   Number of tables: 3
   Number of figures: 8
   Number of references: 50
   Number of words in Abstract: 249
   Number of words in Introduction: 490
   Number of words in Discussion: 1190

d) Nonstandard abbreviations
   APAP, acetaminophen; CAR, constitutive androstane receptor; CYP, cytochrome P450; DME, drug-metabolizing enzyme; NAC, N-acetyl-L-cysteine; Nrf2, NF-E2-related factor-2; PCR, polymerase chain reaction; PB, phenobarbital; TBARS, thiobarbituric acid reactive substances; UGT, UDP-glucuronosyltransferase
Abstract

UDP-glucuronosyltransferase (UGT), a phase II drug-metabolizing enzyme, is expressed in the brain and can catalyze glucuronidation of endogenous and exogenous substrates in the brain. Thus, changes in UGT1A expression could affect homeostasis and drug efficacy. Phenobarbital (PB), a typical inducer of drug-metabolizing enzymes, has been reported to induce oxidative stress and epigenetic changes, which could alter UGT expression in the brain. Here, we aimed to clarify the effects of PB on Ugt1a6 and Ugt1a7 gene expression in rat brains. Sprague-Dawley rats were treated intraperitoneally with PB (80 mg/kg), once daily for 7 days. Ugt1a6 and Ugt1a7 mRNA expression levels were increased in the striatum and thalamus (Ugt1a6: 3.0- and 2.9-fold, respectively; Ugt1a7: 2.6- and 2.6-fold, respectively). Acetaminophen glucuronidation was also increased in the medulla oblongata and thalamus by 1.8- and 1.2-fold, respectively. The induction rates within different brain regions were correlated with Ugt1a6 and Ugt1a7 mRNA expression, and the degree of induction also correlated with that of Nrf2 mRNA. Measurement of oxidative stress markers suggested that PB induced oxidative stress in brain regions in which Ugt1a6 and Ugt1a7 mRNAs were increased. Moreover, histone modifications were altered by PB treatment, resulting in increased histone H3 lysine 4 trimethylation in the striatum and thalamus and decreased histone H3 lysine 9 trimethylation in the thalamus. These results suggested that oxidative stress and histone modifications may promote transcriptional activation of Ugt1a6 and Ugt1a7 genes. In summary, Ugt1a6 and Ugt1a7 mRNA levels were increased by PB treatment, which may alter pharmacokinetics in the brain.
**Introduction**

Many drug-metabolizing enzymes (DMEs) are expressed primarily in the liver and play important roles in the metabolism of various exogenous and endogenous compounds. Because some DMEs are also found in extrahepatic tissues, including the brain, local brain metabolism could affect the efficacy of central-acting drugs and endogenous compounds, independent of liver metabolism (Dutheil et al., 2008; Miksys and Tyndale, 2013).

UDP-glucuronosyltransferase (UGT) catalyzes a major phase II reaction and has been reported to be expressed in brain tissues, neurons, and astrocytes (King et al., 1999; Suleman et al., 1998; Shelby et al., 2003). Therefore, UGT1As in the brain would be involved in mediating the pharmacological effects of several central-acting drugs as UGT substrates, such as acetaminophen (APAP) (Court et al., 2001), amitriptyline (Green et al., 1998), and valproic acid (Ethell et al., 1998). UGT1As also catalyze the glucuronidation of neurotransmitters and neurosteroids, such as serotonin (Krishnaswamy et al., 2003), dopamine (Itaaho et al., 2009), and estradiol (Court, 2005), as endogenous substrates in the brain. Thus, changes in the expression levels of UGT1As in the brain may affect drug efficacy and homeostasis.

The expression levels of UGT are regulated by various inducers through nuclear receptors, such as aryl hydrocarbon receptor (Yueh et al., 2005; Münzel et al., 2003), constitutive androstane receptor (CAR) (Sugatani et al., 2005), and NF-E2-related factor-2 (Nrf2) (Shen and Kong, 2009). Phenobarbital (PB), a major antiepileptic drug, is a typical DME inducer functioning through CAR signaling pathway and activation of
target gene transcription. Ugt1a6 mRNA has been reported to be increased by PB in the rat liver (Kato et al., 2005). Moreover, previous studies have revealed that PB induces oxidative stress in the rat liver and brain (Dostalek et al., 2008; Reeta et al., 2011). Oxidative stress can activate the Nrf2 signaling pathway, and Ugt1a6 and Ugt1a7 mRNA levels are increased by oxidative stress in rat astrocytes (Reeta et al., 2011). Since Ugt1a6 is expressed in the rat brain, neurons, and astrocytes (Shelby et al., 2003; Sulman et al., 1998), PB is thought to have the potential to change the expression of Ugt1a6 and Ugt1a7 isoforms in the rat brain.

PB can also alter DNA methylation and histone modifications (Watson and Goodman, 2002; Lempiäinen et al., 2011). Such epigenetic changes are involved in gene regulation prior to transcriptional activation. In a previous study, PB-mediated changes in DNA methylation and histone modification were shown to be associated with the upregulation of cytochrome P450 (Cyp) 2b10 (a CAR target gene) in mice (Lempiäinen et al., 2011). Moreover, CAR activation has been shown to be related to epigenetic changes at the promoter region of CAR target genes (Chen et al., 2012). Thus, Ugt1a6 and Ugt1a7 can be induced by PB and affect drug metabolism and homeostasis in the brain.

The purpose of this study was to ascertain whether changes of UGT1A6 and UGT1A7 occurred in rat brain due to PB. If such changes occurred, we sought to clarify their mediating mechanisms.
Materials and Methods

Materials

Thiobarbituric acid was purchased from Cayman Chemical Company (Ann Arbor, MI). N-Acetyl-L-cysteine (NAC), APAP, barbital, PB, and 1,1,3,3-tetramethoxypropan were purchased from Wako Pure Chemicals (Osaka, Japan). APAP glucuronide was obtained from Sigma-Aldrich (St. Louis, MO). All other chemicals and solvents were of the highest grade commercially available.

Animal treatment

The present study was approved by the Institutional Animal Care and Use Committee of Meijo University. Eight-week-old male Sprague-Dawley rats (Japan SLC, Hamamatsu, Japan) were treated intraperitoneally once daily for 7 days with PB at a dose of 80 mg/kg/day or with saline as the control. Twenty-four hours after the last treatment, the cerebellum, frontal cortex, parietal cortex, piriform cortex, hippocampus, medulla oblongata, olfactory bulb, striatum, and thalamus were excised from the brain.

RNA extraction and quantitative real-time polymerase chain reaction (PCR)

Total RNA was extracted using TRIzol reagent (Life Technologies, Carlsbad, CA) and was then treated with DNase I (Promega, Madison, WI). Reverse transcription was conducted with ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). Absolute quantitative real-time PCR was performed using the method described by Leong et al. (2007) with slight modifications. Primers were designed for preparation of UGT standard solution (Table 1) and synthesized by Greiner Bio-one (Tokyo, Japan). Using the average molecular weight of the amplified product and Avogadro’s constant, the number of copies
per unit volume was calculated. The standard series and samples were run under the same conditions. PCR was performed using Thermal Cycler Dice instrument from TaKaRa Bio (Shiga, Japan) with SYBR Premix Ex Taq II (TaKaRa Bio). The primers used for quantification of UGT mRNA are described in Table 2 and were commercially synthesized by Greiner Bio-one. The PCR amplification conditions were as follows: initial denaturation at 95°C for 30 s; 40 cycles of denaturation at 95°C for 5 s; and annealing and extension at 60°C for 30 s. Taqman Gene expression assays was used to determine the expression of Cyp2b1 mRNA (Rn01457880_m1; Applied Biosystems, Carlsbad, CA). PCR amplification was performed with the same conditions described above. All data were normalized to the expression level of β-actin. Data are shown as the mean values from five rats in each group.

Preparation of microsomes

Pooled rat brain microsomes were prepared from 10 rats according to the methods described previously (Sakakibara et al., 2015) and stored at -80°C until analysis. Protein concentrations were determined using Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA).

APAP glucuronidation

APAP glucuronidation was determined using the method described by Sakakibara et al. (2014) with slight modifications. In a preliminary study, we confirmed the linearity of the protein concentrations, substrate concentration, and incubation times. The concentrations of APAP and brain microsomes were 1 mM and 0.5 mg/mL, respectively. The reaction mixture was incubated at 37°C for 60 min. Data are presented as the mean of three
independent determinations using pooled brain microsomes from 10 rats.

**Immunoblot analysis**

The pooled cytoplasmic and nuclear extracts of the striatum and thalamus from rat brains and livers were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s instructions. The cytoplasmic and nuclear extracts were collected and stored at -80°C until SDS polyacrylamide gel electrophoresis and immunoblotting. Immunodetection was performed with a polyclonal rabbit anti-CAR antibody (ab35850; abcam, Cambridge, MA) at a 1:1000 dilution. Immunodetection for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Lamin B1 was carried out using anti-GAPDH antibody (ab8245; abcam; 1:500 dilution) and anti-Lamin B1 antibody (ab16048; abcam; 1:5000 dilution), respectively. The bands were scanned using ImageQuant LAS-4010 instrument and quantitated with ImageQuant TL (GE Healthcare Life Science, Uppsala, Sweden).

**Thiobarbituric acid reactive substances (TBARS) measurement**

For determination of TBARS levels, brain tissues from five rats were pooled and homogenized in 10 volumes (w/v) of 1.15% KCl. TBARS was measured according to the method described by Ohkawa et al. (1979). TBARS were calculated as nmol of TBARS per mg of protein.

**Glutathione assay**

For determination of the glutathione levels, brain tissues from five rats were pooled and homogenized in 5% sulfosalicylic acid in an ice-water bath. Homogenates consisting of 100 mg tissue in 1 mL (10%) were centrifuged at 8,000 g for 10 min at 4°C to remove
proteins. Supernatants were assayed for glutathione using GSSG/GSH Quantification Kit (Dojindo, Kumamoto, Japan) according to the manufacturer’s instructions.

**Effects of PB and NAC treatment on Ugt1a6, Ugt1a7 and Cyp2b1 expression in rat hepatocytes**

Hepatocytes were isolated from 5-week-old male Sprague-Dawley rats (n = 5) using a two-step collagenase perfusion method. Drug treatments were initiated 24 h after plating. Hepatocytes were treated with 2 mM PB and/or 10 mM NAC for 72 h and were collected for RNA preparation.

**DNA methylation assay**

Genomic DNA from pooled rat brains (n = 5) was extracted with phenol/chloroform followed by ethanol precipitation (Brilliant et al., 1991) and was assayed for methylated DNA using Methylated DNA Quantification kit (abcam) according to the manufacturer’s instructions.

**Histone modification assay**

Histone extracts from pooled rat brains (n = 5) were prepared using EpiSeeker Histone Extraction Kit (abcam). The histone extracts were assayed for histone modification using Histone H3 (tri-methyl K4), Histone H3 (tri-methyl K9), and Histone H3 (acetyl K9) Quantification Kits (abcam) according to the manufacturer’s instructions.

**Quantification of PB concentrations**

The concentrations of PB in plasma and brain tissues were measured by high-performance liquid chromatography with tandem mass spectrometry. Brain tissue was homogenized in 10 volumes (w/v) of the homogenate buffer containing 10 mM
Tris-HCl, 0.1 mM EDTA, and 20% glycerin. Fifty microliters of brain homogenate or plasma and 200 µL of acetonitrile containing 0.25 µg/mL barbital as internal standard were mixed. The acetonitrile mixtures were vortexed and then centrifuged at 9,000 g for 10 min. Ten microliters of the obtained supernatant was subjected to high-performance liquid chromatography with tandem mass spectrometry. Liquid chromatography was performed using a Prominence instrument, which was equipped with an Inertsil ODS-3 column (3.0 × 150 mm). The column temperature was 40˚C, and the flow rate was 0.2 mL/min. The mobile phase consisted of acetonitrile/10 mM ammonium acetate (40:60 [v/v]). The liquid chromatographic column was connected to an API4000 tandem mass spectrometer operated in the negative electrospray ionization mode. The turbo gas was maintained at a temperature of 300˚C. Mass/charge (m/z) ion transitions were recorded in the multiple reaction-monitoring mode, with m/z 231.0/187.8 for PB and m/z 182.7/139.8 for barbital. The limit of detection for PB was 1.7 pmol with a coefficient of variation of less than 10%. Data are shown as the mean values for five rats in each group.

**Statistical analysis**

Statistical analyses were performed using Student’s paired t-tests with the Kaleida-Graph computer program (Synergy Software, Reading, PA).

**Results**

**Effects of PB on Ugt1a6 and Ugt1a7 mRNA expression in rat brains**

Constitutive expression of Ugt1a6 and Ugt1a7 mRNAs was observed in all nine regions, and the expression levels were 1.5–10% of the expression levels in the liver.
Following treatment with PB, Ugt1a6 and Ugt1a7 mRNA levels were increased in the piriform cortex, hippocampus, medulla oblongata, olfactory bulb, striatum, and thalamus; the degree of induction differed among the nine regions examined in this study (Fig. 1). Ugt1a6 and Ugt1a7 mRNA levels were particularly increased in the striatum and thalamus (Ugt1a6: 3.0- and 2.9-fold, respectively; Ugt1a7: 2.6- and 2.6-fold, respectively). The degrees of induction of Ugt1a6 and Ugt1a7 were correlated ($r = 0.92$, $p < 0.001$).

**Effects of PB on APAP glucuronidation in rat brains**

APAP glucuronidation, which is catalyzed mainly by Ugt1a6 and Ugt1a7, was determined in the medulla oblongata, striatum, and thalamus, where relatively high mRNA induction was observed. Following PB treatment, APAP glucuronidation increased in the medulla oblongata by 1.8-fold (control: 0.23 ± 0.01 pmol/min/mg protein, PB: 0.41 ± 0.01 pmol/min/mg protein). In the thalamus, APAP glucuronidation also increased by 1.2-fold (control: 0.19 ± 0.01 pmol/min/mg protein, PB: 0.23 ± 0.00 pmol/min/mg protein). However, APAP glucuronidation remained unchanged in the striatum (control: 0.23 ± 0.01 pmol/min/mg protein, PB: 0.22 ± 0.01 pmol/min/mg protein).

**Effects of PB on the expression levels of nuclear receptors in rat brains**

The constitutive expression levels of CAR and Nrf2 mRNAs were detected in all nine regions of the brain, with different degrees of expression (Figs. 2 and 4A). Following treatment with PB, CAR mRNA was not changed in any of the brain regions, with the exception of the medulla oblongata (Fig. 2). Although the expression of the nuclear CAR
protein was increased by 1.5-fold in the liver, it was not increased in the striatum or thalamus, where Ugt1a6 and Ugt1a7 mRNA levels were increased by PB (Fig. 3).

Following PB treatment, Nrf2 mRNA was increased in the hippocampus, medulla oblongata, olfactory bulb, striatum, and thalamus by 1.3-, 1.3-, 1.6-, 2.4-, and 2.0-fold, respectively (Fig. 4A). The degree of induction of Nrf2 mRNA by PB was correlated with that of Ugt1a6 and Ugt1a7 mRNAs (Ugt1a6: $r = 0.97$, $p < 0.001$; Ugt1a7: $r = 0.90$, $p < 0.001$) (Fig. 4B).

**Effects of PB on oxidative stress markers in rat brains**

The level of TBARS (lipid peroxidation) and total glutathione (nonenzymatic antioxidant defenses) were significantly increased in the medulla oblongata, olfactory bulb, striatum, and thalamus after PB treatment (Figs. 5A and 5B). HO-1 mRNA (regulated by Nrf2) was increased in all nine regions (Fig. 6), and the fold changes of HO-1 mRNA correlated with those of Ugt1a6 and Ugt1a7 mRNA (Ugt1a6: $r = 0.84$, $p < 0.01$; Ugt1a7: $r = 0.89$, $p < 0.01$).

**Effects of NAC on Ugt1a6, Ugt1a7 and Cyp2b1 mRNA expression in rat hepatocytes treated with PB**

Following PB exposure for 72 h, Ugt1a6 and Ugt1a7 mRNAs were increased by 1.9- and 1.7-fold, respectively, in rat hepatocytes (Fig. 7). NAC treatment decreased the induction of Ugt1a6 and Ugt1a7 mRNAs by 1.1- and 1.2-fold, respectively. PB treatment also increased HO-1 mRNA by 3.0-fold; this effect was inhibited by NAC. Cyp2b1, a representative target gene of CAR, was induced by PB, and unlike Ugt1a6 and Ugt1a7, the level of induction was not decreased by NAC treatment (Fig. 7).
Effects of PB on DNA methylation and histone modifications in rat brains

Following treatment with PB, DNA methylation was unchanged in five brain regions (Fig. 8A). Histone H3 lysine 4 (H3K4) trimethylation was increased by 2.7- and 2.9-fold in the striatum and thalamus, respectively (Fig. 8B), whereas histone H3 lysine 9 (H3K9) trimethylation was decreased by 0.34-fold in the thalamus (Fig. 8C). H3K9 acetylation was unchanged in the five regions (Fig. 8D).

Concentrations of PB in rat brains

The PB concentrations in the brain and plasma were quantified at 1 and 24 h after the last treatment. There were no significant differences in PB concentrations in any brain region at 1 and 24 h (Table 3).

Discussion

In the present study, we found that the expression levels of Ugt1a6 and Ugt1a7 mRNAs in the rat brain were increased by PB. The degree of induction differed among the nine examined brain regions, and those of Ugt1a6 and Ugt1a7 mRNAs were correlated. Therefore, the increases in Ugt1a6 and Ugt1a7 mRNA levels can be attributed to similar mechanisms.

PB is a typical inducer promoting the nuclear translocation of CAR, which is normally sequestered in the cytoplasm by the cytoplasmic CAR retention protein (Kobayashi et al., 2003). CAR translocates to the nucleus and heterodimerizes with the retinoid X receptor (RXR) α. The heterodimer then binds to a PB-responsive enhancer module in the region upstream of the promoter in CAR target genes, such as CYP2B, resulting in
transcriptional activation (Honkakoski et al., 1998). In the present study, the expression of the nuclear CAR protein was increased in the liver following PB treatment, whereas the accumulation of CAR protein in the nucleus was not observed in the striatum and thalamus, where the expression levels of Ugt1a6 and Ugt1a7 mRNAs were increased (Fig. 3). In some brain regions, such as the cortex, hippocampus, striatum, and thalamus, PB and 2,4,6-tryphenuldioxane did not affect CYP2B expression; in contrast, these agents caused a dramatic increase in CYP2B expression in the liver (Upandhya et al., 2002; Pustylnyak et al., 2009; Stamou et al., 2014). These results suggested that another mechanism, not involving CAR, may have contributed to the transcriptional activation of Ugt1a6 and Ugt1a7 in the rat brain.

Nrf2 is activated by oxidative/electrophilic stress and translocates to the nucleus from the cytosol, where it binds to the antioxidant response element with the small Maf protein and leads to transcriptional activation of target genes (Shen and Kong, 2009). Because there is an antioxidant response element in the region upstream of Nrf2 gene, Nrf2 is self-regulated in mice (Miao et al., 2005). Ugt1a6 and Ugt1a7 mRNAs are also increased through transcriptional activation by Nrf2 in mice and rats (Buckley and Klaassen, 2009; Shelby and Klaassen, 2006). In this study, we showed that Nrf2 mRNA was increased by PB and that the degree of induction was correlated with those of Ugt1a6 and Ugt1a7 mRNAs (Fig. 4B). Therefore, Ugt1a6 and Ugt1a7 mRNAs were regulated through the Nrf2 signaling pathway. In fact, the level of TBARS was increased in the brain regions where Ugt1a6 and Ugt1a7 mRNAs were increased following the PB treatment (Fig. 5A). These results suggested that oxidative stress was induced by PB in the rat brain,
consistent with a previous study in rats (Reeta et al., 2011). The brain may be more susceptible to oxidative stress because it contains high levels of unsaturated fatty acids, which are the main targets of free radicals and cellular lipid peroxides. Measurement of TBARS is meaningful as an oxidative stress marker in the brain. Moreover, the level of total glutathione was also increased in some brain regions (Fig. 5B). Such increases in glutathione levels could result from the increase in \( \gamma \)-glutamylcysteine synthetase, which catalyzes the rate-limiting step in the \textit{de novo} synthesis pathway of glutathione. The expression of \( \gamma \)-glutamylcysteine synthetase and the level of glutathione in rat neurons and glia cells are increased by oxidative stress through the Nrf2 signaling pathway (Iwata-Ichikawa et al., 1999; Shih et al., 2003). Because the degree of induction of Ugt1a6 and Ugt1a7 mRNAs was correlated with the degree of induction of Nrf2-target gene HO-1, the oxidative stress induced by PB may activate Nrf2 signaling pathway. To verify this hypothesis, we examined the effects of the antioxidant NAC on the induction of Ugt1a6 and Ugt1a7 mRNAs by PB in rat hepatocytes. Our data showed that NAC exposure inhibited the induction of Ugt1a6, Ugt1a7, and HO-1 mRNAs but not Cyp2b1 mRNA (Fig. 7). These results indicated that Ugt1a6 and Ugt1a7 mRNAs were increased by oxidative stress derived from PB.

H3K4 trimethylation correlates with activation of gene expression, whereas H3K9 trimethylation is associated with gene silencing (Kimura, 2013). Moreover, H3K4 trimethylation is increased by oxidative stress (Niu et al., 2015). In the present study, H3K4 trimethylation was increased in the striatum and thalamus, and H3K9 trimethylation was decreased in the thalamus. Moreover, the degree of induction of
Ugt1a6 and Ugt1a7 mRNAs by PB in the striatum and thalamus was higher than those in other regions. These results suggested that the regional differences in the degree of the induction in Ugt1a6 and Ugt1a7 may be associated with differences in epigenetic changes induced by PB in the rat brain.

From the above results, we hypothesized that oxidative stress generated by PB and histone modifications may be involved in the transcriptional activation of Ugt1a6 and Ugt1a7; however, the degrees of induction were not associated with the concentrations of PB in each of the nine brain regions (Table 3). A capacities and responses to oxidative stress among the nine brain regions may be varied, which would be expected to cause differences in the transcriptional activation of Ugt1a6 and Ugt1a7 among the nine brain regions.

In the present study, PB increased not only Ugt1a6 and Ugt1a7 mRNAs but also APAP glucuronidation in brain regions with relatively high induction of mRNA. Ugt1a6 and Ugt1a7 are mainly involved in the conjugation of planar phenols, including endogenous compounds (e.g., serotonin) and drugs such as APAP, as well as metabolites of carcinogens, such as benzo(a)pyrene-3,6-diphenol (Bock and Köhle 2005). Therefore, Ugt1a6 and Ugt1a7 in the brain may play important roles in detoxification and homeostasis to protect the brain. In the present study, APAP glucuronidation was increased by PB in the medulla oblongata and thalamus where serotonin, a Ugt1a6 substrate, was found (Iceman et al., 2013; Chung et al., 2015). Thus, the concentrations of UGT substrates, including serotonin, may change locally, thereby altering efficacy. However, the increase in APAP glucuronidation was not correlated with the increase in
Ugt1a6 and Ugt1a7 mRNA expression levels in the striatum. A previous report showed that human UGT1A mRNA and protein levels did not always correlate with each other (Izukawa et al., 2009; Ohtsuki et al., 2012; Oda et al., 2012), suggesting that the level of induction of Ugt mRNA does not correlate with the induction of glucuronidation activities. To determine changes in Ugt1a6 and Ugt1a7 enzyme activities in detail may require more specific Ugt1a6 and Ugt1a7 substrates. Similar to previous reports, our data suggested that an unexplained epigenetic mechanism may be involved in the post-transcriptional regulation of Ugt1a6 and Ugt1a7 in the rat brain.

UGTs play important roles in the detoxification of xenobiotics, including drugs and environmental substances, protecting the organism from the effects of hazardous compound. UGTs also function as antioxidants based upon their role in maintaining the redox balance (Kalthoff et al., 2010). Compared with other organs, the brain appears especially susceptible to excessive oxidative stress (Dringen et al., 2000; Bergamini et al., 2004). Hence, the transcriptional activation of UGT isoforms in the brain contributes to the protection of the brain against cytotoxicity.

In summary, in this study, we found that PB induced the expression of Ugt1a6 and Ugt1a7 in rat brains. These changes could affect pharmacological and physiological functions owing to alterations in the concentrations of the drugs in the brain.

Authorship contributions

Participation in research design: Sakakibara, Katoh, and Nadai

Conducted experiments: Sakakibara, Katoh and Kondo
Wrote or contributed to the writing of the manuscript: Sakakibara, Katoh, and Nadai
Reference


Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, and Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by


King CD, Rios GR, Assouline JA, and Tephly TR (1999) Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and


85: 815-821.


Nrf2-expressing glia potently protects neurons from oxidative stress. *J Neurosci* **23**: 3394-3406.


Footnotes

This work was supported in part by JSPS KAKENHI [Grant Number 25460200]; and the Hori Sciences and Arts Foundation.

The authors report no conflicts of interest.
Figure Legends

**Fig. 1.** Changes in Ugt1a6 (A) and Ugt1a7 (B) mRNA expression in response to PB treatment in rat brains.

Each column represents the mean ± SD of three independent determinations. The mRNA expression levels were normalized to the expression of β-actin mRNA. **p < 0.01, ***p < 0.01 compared with the control.

**Fig. 2.** Expression levels of CAR mRNA in rat brains following PB treatment.

The expression of CAR mRNA was calculated as the value relative to that of the control in the cerebellum. The mRNA expression level was normalized to the expression of β-actin mRNA. Each column represents the mean ± SD of three independent determinations. **p < 0.01 compared with the control.

**Fig. 3.** Expression levels of CAR protein in rat brains and liver following PB treatment.

The expression of CAR protein was calculated as the value relative to that of the corresponding control. The protein expression level was normalized to those of GAPDH and Lamin B1 in the cytosol and nucleus, respectively. Each column represents the mean ± SD of three independent determinations. *p < 0.05, **p < 0.01 compared with the control.

**Fig. 4.** Effects of PB on Nrf2 mRNA (A) and correlation analysis between fold inductions of Nrf2 and Ugt1a mRNAs in rat brains (B).
The expression of Nrf2 mRNA was calculated as the value relative to that of the control in the cerebellum. The mRNA expression level was normalized to the expression of β-actin mRNA. Each column represents the mean ± SD of three independent determinations. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control. The x-axis represents the relative expression of Ugt1a mRNA, and the y-axis represents the relative expression of Nrf2 mRNA.

Fig. 5. Effects of PB on TBARS (A) and total glutathione (B) in rat brains.

Each column represents the mean ± SD of three independent determinations. *p < 0.05, **p < 0.01 compared with the control.

Fig. 6. Effects of PB on HO-1 mRNA in rat brains.

The expression of HO-1 mRNA was calculated as the value relative to that of the control in the cerebellum. The mRNA expression level was normalized to the expression of β-actin mRNA. Each column represents the mean ± SD of three independent determinations. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control.

Fig. 7. Inhibition of PB-induced increases in Ugt1a6, Ugt1a7, HO-1 and Cyp2b1 mRNAs in rat hepatocytes by NAC.

The mRNA expression was calculated as the value relative to that of the control. The mRNA expression level was normalized to the expression of β-actin mRNA. Each column represents the mean ± SD of three independent determinations. *p < 0.05, **p <
0.01 compared with the control.

**Fig. 8.** Effects of PB on DNA methylation and histone modifications in rat brains.

Percentages were calculated as the values relative to that of the control in the cerebellum. Each column represents the mean ± SD of three independent determinations. *p < 0.05 compared with the control.
<table>
<thead>
<tr>
<th>Gene</th>
<th>Accession No.</th>
<th>Type</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ugt1a6</td>
<td>NM_057105</td>
<td>Sense</td>
<td>5'-GAGCACCTCAGTGAAACGCAGA-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-sense</td>
<td>5'-ACTCTCTTAGAGGAGCCATCAGG-3'</td>
</tr>
<tr>
<td>Ugt1a7</td>
<td>NM_130407</td>
<td>Sense</td>
<td>5'-CAAGGAAGAGTGTAAGAACCCTT-3'</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-sense</td>
<td>5'-ATTGGGTCATCAGGTCTGGTA-3'</td>
</tr>
</tbody>
</table>
Table 2. Primer sequences used for quantification

<table>
<thead>
<tr>
<th>Gene</th>
<th>Accession No.</th>
<th>Sequence No.</th>
<th>Sequence Anti-sense</th>
<th>Amplicon size (bp)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ugt1a6</td>
<td>NM_057105</td>
<td>Sense 5’-GGGAGAATTCCAAATACACTACAGGAG-3’</td>
<td>Anti-sense 5’-CAGCAAAGTGTTGGTTTCCCCAAAGG-3’</td>
<td>100</td>
<td>Tian et al. (2005)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sense 5’-CAGACCCCGGTGACTATGACA-3’</td>
<td>Anti-sense 5’-CAACGTGAAGTCTGTGCGTAACA-3’</td>
<td>73</td>
<td>Tian et al. (2005)</td>
</tr>
<tr>
<td>CAR</td>
<td>NM_022941</td>
<td>Sense 5’-CGGAGTATAAAACAGCGCATCTCA-3’</td>
<td>Anti-sense 5’-AAGCAGCAGGATCATAGCA-3’</td>
<td>72</td>
<td>Tian et al. (2005)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sense 5’-CTCCAGGTTGCCACATTC-3’</td>
<td>Anti-sense 5’-AAGCAGCGGATCATAGCA-3’</td>
<td>239</td>
<td>Yoshinari et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>NM_012940</td>
<td>Sense 5’-TGCTCGCATGAACACTG-3’</td>
<td>Anti-sense 5’-TCCTCTGTCACAGTGCCCT-3’</td>
<td>123</td>
<td>Thulluri et al. (2012)</td>
</tr>
<tr>
<td>β-actin</td>
<td>NM_031144</td>
<td>Sense 5’-CTGGGCCTCAGTCCACCTT-3’</td>
<td>Anti-sense 5’-GGGCCGGACTCAGTGACTC-3’</td>
<td>65</td>
<td>Tian et al. (2005)</td>
</tr>
</tbody>
</table>
Table 3. Concentrations of PB in the brain and plasma at 1 and 24 h after administration

<table>
<thead>
<tr>
<th></th>
<th>PB (µg/mg protein)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>291.1 ± 32.0</td>
<td>9.0 ± 6.3</td>
</tr>
<tr>
<td>Frontal cortex</td>
<td>320.1 ± 34.0</td>
<td>9.1 ± 5.5</td>
</tr>
<tr>
<td>Piriform cortex</td>
<td>307.2 ± 23.7</td>
<td>9.1 ± 5.5</td>
</tr>
<tr>
<td>Parietal cortex</td>
<td>324.2 ± 34.5</td>
<td>8.9 ± 5.2</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>311.8 ± 19.4</td>
<td>9.6 ± 6.5</td>
</tr>
<tr>
<td>Medulla oblongata</td>
<td>322.5 ± 27.5</td>
<td>9.7 ± 6.2</td>
</tr>
<tr>
<td>Olfactory bulb</td>
<td>306.7 ± 30.9</td>
<td>9.1 ± 6.0</td>
</tr>
<tr>
<td>Striatum</td>
<td>320.3 ± 35.6</td>
<td>8.9 ± 6.1</td>
</tr>
<tr>
<td>Thalamus</td>
<td>325.7 ± 29.9</td>
<td>9.8 ± 6.0</td>
</tr>
<tr>
<td>Plasma</td>
<td>76.1 ± 9.5</td>
<td>2.8 ± 1.7</td>
</tr>
</tbody>
</table>

*µg/mL
Relative copy number of mRNA
($\times 10^4/\mu g$ total RNA)

Fig. 1

Liver
Cerebellum
Frontal cortex
Parietal cortex
Piriform cortex
Hippocampus
Medulla oblongata
Olfactory bulb
Striatum
Thalamus

Control

PB

A

B

Ugt1a6

Ugt1a7

This article has not been copyedited and formatted. The final version may differ from this version.

DMD Fast Forward. Published on December 18, 2015 as DOI: 10.1124/dmd.115.067439

at ASPET Journals on May 27, 2022 dmd.aspetjournals.org Downloaded from
Fig. 4

A

Nrf2 mRNA (arbitrary unit)

Cerebellum  Frontal cortex  Parietal cortex  Hippocampus  Medulla oblongata  Olfactory bulb  Striatum  Thalamus

Control  PB

B

Fold induction of Ugt1a6 mRNA

$\begin{align*}
    r &= 0.97 \\
p &< 0.001
\end{align*}$

Fold induction of Ugt1a7 mRNA

$\begin{align*}
    r &= 0.90 \\
p &< 0.001
\end{align*}$

Fold induction of Nrf2 mRNA
Fig. 5

A

TBARS (µmol/mg protein)

- Cerebellum
- Frontal cortex
- Parietal cortex
- Piriform cortex
- Hippocampus
- Medulla oblongata
- Olfactory bulb
- Striatum
- Thalamus

B

Total glutathione (µmol/g wet tissue)

- Control
- PB

* * *
Fig. 6

HO-1 mRNA (arbitrary unit)

Cerebellum
Frontal cortex
Parietal cortex
Piriform cortex
Hippocampus
Medulla oblongata
Olfactory bulb
Striatum
Thalamus

1.5
1.0
0.5
0.0

* * *
Fig. 7

Fold induction of mRNA

- PB
- NAC
- PB+NAC

Ugt1a6  Ugt1a7  HO-1  Cyp2b1

*  **  *  **

DMD Fast Forward. Published on December 18, 2015 as DOI: 10.1124/dmd.115.067439

at ASPET Journals on May 27, 2022 dmd.aspetjournals.org Downloaded from
Fig. 8

A

DNA methylation (%)

Cerebellum
Hippocampus
Medulla oblongata
Striatum
Thalamus

B

H3K4 trimethylation (%)

C

H3K9 trimethylation (%)

D

H3K9 acetylation (%)

H3K9 acetylation (%)

Cerebellum
Hippocampus
Medulla oblongata
Striatum
Thalamus

*
Correction to “Effects of Phenobarbital on Expression of UDP-Glucuronosyltransferase 1a6 and 1a7 in Rat Brain”

The above article [Sakakibara Y, Katoh, M, Kondo Y, and Nadai Masayuki, (2016) Drug Metab Dispos 44:370–377] was published with a typographical error within Figure 3.

“Struatum” should have appeared as “striatum”.

The corrected figure appears below in this erratum.

The authors regret this error and any inconvenience it may have caused.

![Corrected Figure](image-url)